Latest GU Updates from ASCO 2010

posted Jun 18 2010
We would like to thank Drs Lori Wood and Daniel Heng for the latest GU updates.

Localized Prostate Cancer: NCIC PR.3 ADT plus RT vs. ADT alone

Renal Cell Carcinoma: Prognostic Genome Markers

Bladder Cancer: Cisplatin/Gemcitabine/Paclitaxel vs. observation in the adjuvant setting

Germ Cell Cancer: BEP vs. High Dose Chemotherapy in Poor Prognosis Patients

Ovarian Cancer: Bevacizumab

Metastatic Prostate Cancer: Denosumab

Metastatic Prostate Cancer: Bevacizumab

Metastatic Prostate Cancer: Cabazitaxel

Metastatic Prostate Cancer: High Dose Calcitriol

Bladder Cancer: Carboplatin/Gemcitabine vs. Methotrexate/Carboplatin/Vinblastine

Bladder Cancer: Chemoradiation vs. Radiation in Localized Disease